News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,216 Results
Type
Article (40933)
Company Profile (267)
Press Release (681006)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204674)
Career Advice (2025)
Deals (35534)
Drug Delivery (111)
Drug Development (81386)
Employer Resources (173)
FDA (16417)
Job Trends (14947)
News (346409)
Policy (32730)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2571)
Accelerated approval (34)
Adcomms (24)
Allergies (144)
Alliances (49575)
ALS (170)
Alzheimer's disease (1676)
Antibody-drug conjugate (ADC) (314)
Approvals (16688)
Artificial intelligence (520)
Autoimmune disease (159)
Automation (42)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (192)
Biotechnology (174)
Bladder cancer (159)
Brain cancer (57)
Breast cancer (644)
Cancer (4850)
Cardiovascular disease (406)
Career advice (1710)
Career pathing (36)
CAR-T (283)
CDC (45)
Celiac Disease (2)
Cell therapy (748)
Cervical cancer (36)
Clinical research (69615)
Collaboration (1716)
Company closure (4)
Compensation (1172)
Complete response letters (57)
COVID-19 (2714)
CRISPR (93)
C-suite (863)
Cystic fibrosis (143)
Data (6290)
Decentralized trials (2)
Denatured (25)
Depression (134)
Diabetes (504)
Diagnostics (6710)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (255)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (233)
Earnings (90260)
Editorial (57)
Employer branding (21)
Employer resources (152)
Events (117398)
Executive appointments (980)
FDA (19564)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1479)
Gene editing (199)
Generative AI (44)
Gene therapy (597)
GLP-1 (967)
Government (4664)
Grass and pollen (6)
Guidances (384)
Healthcare (18880)
HIV (62)
Huntington's disease (45)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (58)
Indications (118)
Infectious disease (2989)
Inflammatory bowel disease (193)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (254)
Interviews (316)
IPO (16643)
IRA (50)
Job creations (3643)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (86)
Layoffs (547)
Leadership (32)
Legal (7951)
Liver cancer (91)
Longevity (15)
Lung cancer (655)
Lymphoma (381)
Machine learning (42)
Management (59)
Manufacturing (808)
MASH (164)
Medical device (13778)
Medtech (13834)
Mergers & acquisitions (19967)
Metabolic disorders (1274)
Multiple sclerosis (164)
NASH (16)
Neurodegenerative disease (320)
Neuropsychiatric disorders (88)
Neuroscience (2919)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4515)
Now hiring (68)
Obesity (598)
Opinion (262)
Ovarian cancer (167)
Pain (199)
Pancreatic cancer (230)
Parkinson's disease (283)
Partnered (33)
Patents (507)
Patient recruitment (496)
Peanut (57)
People (58913)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21701)
Phase 2 (30636)
Phase 3 (22826)
Pipeline (5430)
Policy (285)
Postmarket research (2564)
Preclinical (9202)
Press Release (64)
Prostate cancer (240)
Psychedelics (48)
Radiopharmaceuticals (283)
Rare diseases (846)
Real estate (5955)
Recruiting (70)
Regulatory (24543)
Reports (53)
Research institute (2391)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (80)
Schizophrenia (148)
Series A (240)
Series B (191)
Service/supplier (11)
Sickle cell disease (97)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3615)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1012)
Venture capital (89)
Weight loss (381)
Women's health (93)
Worklife (18)
Date
Today (143)
Last 7 days (560)
Last 30 days (2334)
Last 365 days (29880)
2026 (3946)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (84)
Alaska (7)
Arizona (310)
Arkansas (13)
Asia (39237)
Australia (6414)
California (11388)
Canada (3313)
China (1103)
Colorado (480)
Connecticut (483)
Delaware (340)
Europe (84603)
Florida (1708)
Georgia (360)
Hawaii (3)
Idaho (61)
Illinois (870)
India (69)
Indiana (526)
Iowa (22)
Japan (436)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1394)
Massachusetts (8147)
Michigan (327)
Minnesota (631)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3023)
New Mexico (28)
New York (3002)
North Carolina (1465)
North Dakota (8)
Northern California (5574)
Ohio (337)
Oklahoma (21)
Oregon (41)
Pennsylvania (2303)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (67)
South Dakota (1)
Southern California (4434)
Tennessee (177)
Texas (1755)
United States (40367)
Utah (340)
Vermont (1)
Virginia (264)
Washington D.C. (81)
Washington State (926)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
722,216 Results for "exicure inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Exicure, Inc. Reports Third Quarter 2025 Financial Results
November 10, 2025
·
6 min read
Press Releases
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
January 21, 2026
·
3 min read
Press Releases
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
February 5, 2026
·
4 min read
Press Releases
Exicure, Inc. Reports Second Quarter 2025 Financial Results
August 11, 2025
·
6 min read
Press Releases
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
August 5, 2025
·
1 min read
Press Releases
Exicure, Inc. Reports First Quarter 2025 Financial Results
June 27, 2025
·
6 min read
Press Releases
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
December 9, 2025
·
4 min read
Press Releases
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
October 6, 2025
·
6 min read
Deals
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”).
May 23, 2024
·
3 min read
Press Releases
Exicure, Inc. Reports Full Year 2024 Financial Results
March 18, 2025
·
7 min read
1 of 72,222
Next
